In our earlier discussion, we spoke of negative EV companies in the Financial Services sector. We also discussed the reasons as to why these companies have a negative EV, laying stress on the possible calculation errors on part of the database providers and structural problems on part of these companies. We also spoke on banking regulations and geographical distribution of these companies.
In our current discussion we intend to focus on sectors other than Financial Services, and try and understand the reasons as to why companies in these sectors could fall in the negative EV category, and more importantly are these prudent investment opportunities?
In our study, we noticed that other than the financial services sector, a significantly large number of companies with negative EV belonged to sectors such as Metals and Mining, Computer Hardware & Software Services, Electricals and Electronics, Retail and Telecom along with Biotech, Health and pharmaceutical companies to name a few. We continue to discuss these sectors below.
Metals & Mining: Prior to the recent market meltdown, the mining companies had already been experiencing a severe correction since the commodity prices peaked in 2007. Despite rising and historically high metal prices, the market witnessed a flight of capital, since the summer of 2007. The credit markets collapsed in September 2008 causing another dip in both prices of mining stocks and the underlying commodities. Most are down over 80% from their 2007 highs and hence, many mining stocks are now trading at a market capitalization much lesser than their cash holdings. This again leads to negative EV for companies within this sector.
Computer Hardware and Software Services: Outlook for the information technology (IT) sector is negative based on weak market demand as capital investments decline and consumer spending reduces significantly. Financial services sector, which is the worldwide leader in terms of IT spending, is experiencing the most severe reduction in spending with the hardware sector being most affected. While this sector’s revenue is strongly correlated to general economic conditions, some subsectors suffer more than others. Hardware is most susceptible to this downturn due to its large exposure to the financial services sector, while most IT services, with the exception of the consulting and systems integration business and software companies receive a significant amount of predictable recurring revenue from long-term maintenance contracts. Overall, the technology sector seems to be struggling and market caps in most cases are at their lowest, but many of the biggest names aren’t hurting for cash. In fact, they’re swimming in it. So the question facing companies and investors is what can be done with all that cash. The options, however, are actually rather limited — buy another company, buy back shares, boost research and development spending or increase dividends. Thus negative EV companies in this sector may not necessarily be a good buy.
Electronics Manufacturing Services: A negative outlook on the EMS (Electronics Manufacturing Services) sector largely reflects expectations for a weakening global economy to pressure operating results, particularly due to revenue decline particularly from IT hardware, mobiles and consumer electronics. The sector’s ability to sustain profit margins near current levels and produce positive net returns on capital are being, and will further be challenged in the weakened economic environment. Conversely, solid liquidity and minimal near term maturities for the EMS companies should provide significant margin in managing through this downturn.
As for the EMS companies, these are expectedly conserving cash and liquidity supported by reduced working capital requirements in a slow down environment and minimizing their debt. With market caps at their lowest levels these companies are hence prominent in the list of companies with a negative EV.
Retail: Retail sector has a strong correlation with people’s income and spending. Given the market slump, Retail has experienced a very strong decline in demand. Retail sector covered in this study includes a broad range of sub sectors such as Apparel Retailers, Broad line Retailers, Clothing & Accessories, Diamonds & Gemstones, Durable Household products, Footwear, Furnishings, Home Improvement Retailers, Nondurable Household Products, Personal Products, Specialty Retailers and Toys.
We noticed an interesting fact – for this sector, enterprise value provided by financial information providers may not have captured all of the debt outstanding in the firm. With a retail firm, EV should ideally include the present value of all lease commitments as its debt. EV, which we see for Wal-Mart, Target and Best Buy, is hence understated and not many companies in this sector would actually have a negative EV. Secondly, the cash that is netted out to get to enterprise value is usually from the most recent financial statement (rather than the current date used for market cap). Given how quickly firm’s burn through cash, what can be seen on the balance sheet may not reflect what the firm currently has as a cash balance, thus flawing the EV calculations.
Healthcare, Pharmaceuticals and Biotech: In the Biotech space, numerous companies are currently trading under their cash value, meaning they could theoretically empty their bank accounts and pay out a dividend greater than their stock price. Or put another way, these companies currently are at their lowest on market capitalization and lye in the negative EV category. This, prima facie looks like a good investment opportunity, however, actually may not be so. When this last happened on a widespread basis, in 2003, buying companies under cash in the Biotech space made for a good short-term play in a few cases. But in the long run, it was more often than not a losing bet. Companies that get that beaten down, even in a brutal market that doles out punishment for little reason, find it hard to climb back. For e.g. buying Human Genome Sciences when it traded under cash value in 2003 was smart, as long as it was sold in 2004 or 2005. Currently, the stock is worth far less than it was at its post-genomic nadir, because its cash pile has continued to dwindle. A few bits of bad clinical news have recently added new members to the negative enterprise value club, Avigen, for instance, which currently has $1.89 per share in cash but a stock price of only 61 cents after the failure of its multiple sclerosis drug in phase 2.
Amidst consistent reports that there is plenty of cash especially in the U.S. pharmaceutical industry, there may be concerns about the challenges of accessing that cash due to the serious tax implications if the cash earned overseas comes back to the US. Pharmaceutical companies seem to be in no mood to repatriate this cash back home. A Moody report looked at nine companies: Amgen, Bristol-Myers Squibb, Eli Lilly, Genentech, Johnson & Johnson, Merck, Pfizer, Schering-Plough and Wyeth, noting that almost 70 percent of the companies’ rise in investments is in offshore cash and that bringing it back could cost nearly 30 percent in taxes. Hence, even though we notice plenty of Biotech companies falling in the negative EV category, in the current economic scenario these may not necessarily be prudent investment opportunities.
Closing remarks
Hoarding cash and its equivalents isn’t always a good thing. Cash doesn’t tend to return much, and having a big pile of it around could either invite a takeover or tempt a company to make a bad acquisition. Still, cash provides an important cushion if business slows down, particularly for those companies carrying significant debt. However, a company with a low debt, high cashand negative EV, would ost likely be susceptible to an acquisition.